Prevalence of Depression, Anxiety, and Stress among Breast Cancer Patients at a Tertiary Care Hospital in Faisalabad, Pakistan
Abstract
Abstract Views: 447
The prevalence of depression in the patients of breast cancer is very common. The diagnosis of cancer produces stress, anxiety, and fear of pain and death in patients, all of which affect their physical and emotional wellbeing. These factors hinder the treatment of cancer because patients lose their will to live a happy and healthy life. The quality of life of people with psychiatric symptoms remains poor. Furthermore, there is a considerable risk that depressive symptoms in patients with breast cancer can lead to physical impairment and prolong mortality. The current descriptive and cross-sectional study was designed to determine depression, anxiety, and stress (DAS) levels in breast cancer patients at a tertiary care hospital in Faisalabad, Pakistan. The questionnaire included the socio-demographic, disease, and DAS related questions. A total of 138 women with breast cancer were included. The data was analyzed using SPSS software. The results showed that 38% of women had extremely severe depression, 68% were suffering from extremely severe anxiety, and 34% were facing extremely severe stress. The study showed that different factors were affecting the DAS scale, such as illiteracy (46.40%), occupation (labour 60.90%) and low income (76.80%) of husbands, sad reaction of families (60.10%), and the fear of chemotherapy (44.20%). Cancer patients need special attention and treatments to avoid emotional distress during their disease journey. This currebt study helps the healthcare professionals to provide psychological treatment to these patients.
Downloads
References
Podvorica E, Kraja J, Rrustemi N, Dugolli X, Hyseni E. Anxiety and depression in patients with breast cancer: a cross-sectional study. Maced J Med Sci. 2022;10(G):138–143. https://doi.org/10.3889/oamjms.2022.8310
Álvarez-Pardo S, de Paz JA, Romero-Pérez EM, et al. Related factors with depression and anxiety in mastectomized women breast cancer survivors. Int J Environ Res Public Health. 2023;20(4):e2881. https://doi.org/10.3390/ijerph20042881
Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176:519–533. https://doi.org/10.1007/s10549-019-05271-3
Akkol‐Solakoglu S, Hevey D. Internet‐delivered cognitive behavioural therapy for depression and anxiety in breast cancer survivors: Results from a randomised controlled trial. Psycho‐Oncol. 2023;32(3):446-456. https://doi.org/10.1002/pon.6097
Biparva AJ, Raoofi S, Rafiei S, et al. Global depression in breast cancer patients: systematic review and meta-analysis. PLoS One. 2023;18(7):e0287372. https://doi.org/10.1371/journal.pone.0287372
Breidenbach C, Heidkamp P, Hiltrop K, et al. Prevalence and determinants of anxiety and depression in long-term breast cancer survivors. BMC Psych. 2022;22(1):e101. https://doi.org/10.1186/s12888-022-03735-3
Sadaqa D, Farraj A, Naseef H, Alsaid H, Al-Shami N, AbuKhalil AD. Risk of developing depression among breast cancer patients in Palestine. BMC Cancer. 2022;22(1):e295. https://doi.org/10.1186/s12885-022-09420-8
Aryankhesal A, Ghashghaee A, Sardari E, et al. Prevalence of depression in patients with cancer in Iran: a systematic review and meta-analysis. BMJ Support Palliat Care. 2022;12(e4):e518–e525. http://dx.doi.org/10.1136/bmjspcare-2018-001724
Okati-Aliabad H, Ansari-Moghadam A, Mohammadi M, Kargar S, Shahraki-Sanavi F. The prevalence of anxiety and depression and its association with coping strategies, supportive care needs, and social support among women with breast cancer. Support Care Cancer. 2022;30:703–710. https://doi.org/10.1007/s00520-021-06477-2
McNeish BL, Richardson JK, Whitney DG. Chemotherapy‐induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors. Eur J Cancer. 2022;31(6):e13648. https://doi.org/10.1111/ecc.13648
Lv D, Lan B, Zhang L, Sun X, Yang M, Ma F. Association between depression and anxiety status of breast cancer patients before adjuvant chemotherapy and chemotherapy‐induced adverse events. Cancer Med. 2023;12(4):4794–4800. https://doi.org/10.1002/cam4.5283
Soqia J, Al-Shafie M, Agha LY, et al. Depression, anxiety and related factors among Syrian breast cancer patients: a cross-sectional study. BMC Psych. 2022;22(1):e796. https://doi.org/10.1186/s12888-022-04469-y
Turdaliyeva B, Karibayeva I, Bagiyarova F, Zainal NZ, Kussainova D. Prevalence and associated factors of depression symptoms in women newly diagnosed with breast cancer in Kazakhstan. Asian Pacific J Cancer Preven. 2022;23(7):e2483. https://doi.org/10.31557/APJCP.2022.23.7.2483
Zeilinger E, Oppenauer C, Knefel M, et al. Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study. Epidemiol Psychiatr Sci. 2022;31:e74. https://doi.org/10.1017/S2045796022000592
Alwhaibi M, AlRuthia Y, Sales I. The impact of depression and anxiety on adult cancer patients’ health-related quality of life. J Clin Med. 2023;12(6):e2196. https://doi.org/10.3390/jcm12062196
Naser AY, Hameed AN, Mustafa N, et al. Depression and anxiety in patients with cancer: a cross-sectional study. Front Psychol. 2021;12:e1067. https://doi.org/10.3389/fpsyg.2021.585534
Alquraan L, Alzoubi KH, Rababa’h S, Karasneh R, Al-Azzam S, Al-Azayzih A. Prevalence of depression and the quality-of-life of breast cancer patients in Jordan. J Multidiscip Health. 2020:1455–1462. https://doi.org/10.2147/JMDH.S277243
Alagizy H, Soltan M, Soliman S, Hegazy N, Gohar SF. Anxiety, depression and perceived stress among breast cancer patients: single institute experience. Middle East Curr Psych. 2020;27(1):e29. https://doi.org/10.1186/s43045-020-00036-x
Stöckigt DMB, Kirschbaum B, Carstensen DMM, Witt DMCM, Brinkhaus DMB. Prophylactic acupuncture treatment during chemotherapy in patients with breast cancer–results of a qualitative study nested in a randomized pragmatic trial. Integr Cancer Ther. 2021;20:1–10. https://doi.org/10.1177/15347354211058207
Copyright (c) 2023 Tanbeela Perveen, Rabbia Jawad, Iqra Afzal, Noreen Iftikhar, Bushra Aslam, Rabia Najeeb, Abida Nasreen
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal
